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Abstract 
Background: A specific psychopathology of addiction has been proposed and described using the self‑report symp‑
tom inventory (SCL‑90), leading to a 5‑factor aggregation of psychological/psychiatric symptoms: ‘worthlessness and 
being trapped’, ‘somatic symptoms’, ‘sensitivity‑psychoticism’, ‘panic‑anxiety’ and ‘violence‑suicide’ in various popula‑
tions of patients with heroin use disorder (HUD) and other substance use disorders (SUDs). These clusters of symp‑
toms, according to studies that have highlighted the role of possible confounding factors (such as demographic and 
clinical characteristics, active heroin use, lifetime psychiatric problems and kind of treatment received by the patients), 
seem to constitute a trait rather than a state of the psychological structure of addiction. These five psychopathological 
dimensions defined on the basis of SCL‑90 categories have also been shown to be correlated with the outcomes of a 
variety of agonist opioid treatments. The present study aims to test whether the 5‑factor psychopathological model of 
addiction correlates with the outcome (retention rate) of patients with SUDs entering a therapeutic community (TC) 
treatment.
Methods: 2016 subjects with alcohol, heroin or cocaine dependence were assigned to one of the five clusters on the 
basis of the highest SCL‑90 factor score shown. Retention in treatment was analysed by means of the survival analysis 
and Wilcoxon statistics for comparison between the survival curves. The associations between the psychopathologi‑
cal subtypes defined by SCL‑90 categories and length of retention in treatment, after taking into account substance of 
abuse and other sociodemographic and clinical variables, were summarized using Cox regression.
Results: Patients with cocaine use disorder (CUD) showed poorer outcomes than those with heroin dependence 
(HUD). Prominent symptoms of “worthlessness‑being trapped” lead to a longer retention in treatment than in the 
case of the other four prominent psychopathological groups. At the multivariate level, age, detoxified status and total 
number of psychopathological symptoms proved to influence outcome negatively, especially in CUD. Somatic symp‑
toms and violence‑suicide symptoms turned out to correlate with dropout from residential treatment.
Conclusions: The SCL‑90 5‑factor dimensions can be appropriately used as a prognostic tool for drug‑dependent 
subjects entering a residential treatment.
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Background
The identification of a specific psychopathology of her-
oin use disorders (HUDs) is a major issue that has only 
been addressed recently [1, 2]. Even though addiction 
has often been labelled as a form of mental illness, there 
is no consensus so far about the core of this disease or 
the clinical covariates of addictive behaviours. Craving, 
in fact, which deserves to be considered one of the main 
features of addiction, was only added as a diagnostic cri-
terion in the latest version of DSM [3]. The question of 
the existence of a specify psychopathology of addiction 
arises from the evidence of a high degree of association 
between the core symptoms of addiction and symptoms 
of other psychiatric diseases [4–6]. Moreover, further 
neurobiological and clinical considerations highlight the 
strong sharing of features between addiction per se and 
other psychopathological disorders, especially in the 
mood, anxiety and impulse/control domains, thus query-
ing the classical model of psychiatric ‘comorbidity’ [7].
Initially, by applying an exploratory principal compo-
nent factor analysis (PCA) to the 90 items in the SCL-
90 checklist in a sample of 1055 heroin addicts entering 
agonist opioid treatment (AOT), a 5-factor solution was 
identified: the first factor reflected a depressive ‘worth-
lessness and being trapped’ dimension; the second fac-
tor picked out a “somatic symptoms” dimension; the 
third identified a ‘sensitivity-psychoticism’ dimension; 
the fourth a ‘panic-anxiety’ dimension; and the fifth a 
‘violence-suicide’ dimension. [1]. The same methodol-
ogy applied in a different sample of 1195 HUD subjects 
entering a therapeutic community (TC) Treatment led 
to the identification of the same five psychopathological 
dimensions [2]. Sociodemographic factors, clinical char-
acteristics such as active heroin use, lifetime psychiatric 
problems, and kind of treatment received by the patient 
did not seem to substantially influence the five SCL-90 
defined aggregation of symptoms [2, 8, 9].
Given the high susceptibility of patients suffering from 
substance dependence to leaving treatment programmes, 
retention has been historically regarded as a proxy for the 
effectiveness of interventions. Research on this topic has 
explored the potential predictors of retention in treat-
ment by investigating sociodemographic profiles, clinical 
conditions and treatment-related factors. Given the high 
prevalence of psychiatric symptoms or overt psychiatric 
conditions in substance use disorders, the impact of their 
presence or severity has properly been considered to be 
one of the determinants of treatment retention [10–18].
The present study aims to test if the 5-factor solution 
psychopathological model of addiction correlates with 
outcome (retention rate) of SUD subjects entering a TC 
Treatment.
Methods
Design of the study
A prospective longitudinal approach was performed 
on the evaluation of therapeutic community treat-
ments and outcomes (The VOECT) cohort study. The 
VOECT study was conducted in eight Italian regions in 
2008–2009, recruiting a total of 2533 patients entering 
a TC treatment for substance use disorder [19]. For the 
present study, specific inclusion criteria were applied: (i) 
minimum age of 18, (ii) diagnosis of heroin, cocaine or 
alcohol substance use disorder (SUD) based on a clini-
cal judgment, (iii) outcome data (dropout from TC treat-
ment). Sociodemographic information and replies to 
SCL-90 questionnaires were collected at the baseline (at 
entry into treatment). These criteria lead to a definitive 
sample of 2016 subjects.
All subjects examined filled in an informed consensus 
document to enable them to participate in this study. The 
study was conducted in accordance with internationally 
accepted criteria and dispositions for ethical research.
Sample
The sample consisted of 2016 SUD patients diagnosed 
according to a clinical judgement; 1693 (84.0%) of 
them were males and 323 (16.0%) females. At the time 
of the recruitment, the average age of the sample was 
35.28 ± 8.6 years (minimum 18, maximum 74). Length of 
education was less than 8 years in 1600 (79.4%) patients. 
1781 (88.3%) were single. 1598 (79.3%) were unemployed. 
1471 (73.0%) subjects lived at home and 545 (27.0%) 
alone.
Instruments
Self‑report symptom inventory (SCL‑90)
Developed by Derogatis and colleagues [20], the SCL90 
consists of 90 items, each rated on a 5-point scale of 
distress. It is a self-report clinical rating scale oriented 
to the collection of symptomatic behaviours of psychi-
atric outpatients. Among heroin-dependent patients, 
the 90 items reflected the five primary symptom dimen-
sions which are believed to underlie the large major-
ity of symptom behaviours observed in this kind of 
patient: worthlessness-being trapped, somatic symptoms, 
Keywords: Addiction, Alcohol, Cocaine, Dropout, Heroin, Psychopathology, Retention, SCL‑90, Therapeutic 
community treatment
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sensitivity-psychoticism, panic-anxiety and violence-sui-
cide [1].
The ‘worthlessness-being trapped’ dimension reflects 
a broad range of the symptoms typical of the clinical 
depressive syndrome. This dimension mirrors feelings 
of worthlessness and of being trapped or caught. The 
‘somatic symptoms’ dimension reflects distress arising 
from perceptions of body dysfunctions. The ‘sensitivity-
psychoticism’ dimension focuses on feelings of a full 
continuum of psychotic behaviours. The ‘panic-anxiety’ 
dimension subsumes a set of symptoms and experiences 
usually clinically associated with a high level of manifest 
anxiety. The ‘violence-suicide’ dimension is organized 
around three categories of hostile behaviour: thoughts, 
feelings, and actions; it also comprises thoughts of death 
and suicidal ideation.
In several previous studies, these five dimensions were 
empirically established and validated [2, 8, 9, 21]. SCL-90 
was administered within 15 days after entry into the TC 
programme.
Other instruments
Information on the sociodemographic and clinical char-
acteristics of the patients included in the study was col-
lected through a research questionnaire administered at 
the time of entering TC.
Data analysis
The sample was divided into three groups according 
to the primary substance of abuse (Alcohol, Heroin or 
Cocaine). We further classified patients according to 
which of the five SCL-90 dominant dimensions were 
found in each of them. SCL-90 factor scores were stand-
ardized into z scores in order to make scores comparable. 
Each subject was assigned to one of the five subtypes on 
the basis of the highest z scores achieved (named “promi-
nent psychopathological dimensions”). This procedure 
gives the opportunity to classify subjects on the basis of 
the highest symptomatological cluster, thus overcoming 
the problem of identifying a cut-off point for the inclu-
sion of patients in the clusters. The subtypes are clearly 
distinct, as shown by analysing the mean z-scores and 
95% confidence interval (CI 95%) across the factors for 
each dominant group [1].
Retention in treatment was analysed by means of the 
survival analysis and Wilcoxon statistics for comparison 
between the survival curves. For the purpose of this anal-
ysis, the term ‘censored observations’ refers to patients 
who were still in treatment at the end of the study or were 
leaving treatment for reasons unrelated to the treatment 
itself (e.g. patients moving on other therapeutic commu-
nities, due to imprisonment for old crimes). We consid-
ered it to be a negative outcome (terminal event) when 
a patient abandoned the residential treatment or was 
expelled from the residential treatment. We compared 
the patients’ survival rates according to the primary sub-
stance of abuse and according to the psychopathological 
subtypes. The association between psychiatric subtypes 
and retention in treatment was summarized using Cox 
regression. In our model, we included sociodemographic 
and clinical variables that may act as confounding factors 
(age, gender, marital status, detoxification status, living 
conditions, primary substance of abuse, severity of psy-
chopathological symptoms).
We used the statistical routines of SPSS, version 20.0.
Results
2016 patients were observed for 1  month, 1724 for 
2 months, 1451 for 3 months, 1207 for 4 months, 861 for 
5  months, 692 for 6  months, 541 for 7  months, 439 for 
8 months, 346 for 9 months, 269 for 10 months, 206 for 
11 months, 161 for 12 months, 126 for 13 months, 86 for 
14 months 47 for 15 months and 9 for 16 months. At the 
end of the study, the cumulative retention rate was 0.39.
Retention rate according to the primary substance 
of abuse
The primary substance of abuse was alcohol in 401 
(19.9%) of the part, heroin or other opioids in 1045 
(51.8%) and cocaine in 570 (28.3%). Figure 1 shows reten-
tion rate according to the primary substance of abuse. 
Retention rates differed statistically between the three 
subgroups (Wilcoxon statistics = 6.59; df = 2; p = 0.037). 
In particular, 64.3% of the patients primarily using alco-
hol were censored, compared with 57.4% of the patients 
primarily using cocaine (Wilcoxon statistics  =  6.54; 
df = 1; p = 0.011).
Retention rate according to the prominent 
psychopathology at residential treatment entry
The ‘worthlessness-being trapped’ dimension was promi-
nent in 298 (14.8%) patients, ‘somatic symptoms’ in 456 
(22.6%), ‘sensitivity-psychoticism’ in 406 (20.1%); ‘panic-
anxiety’ in 518 (25.7%) and ‘violence-suicide’ in 338 
(16.8%). Figure  2 shows the retention rate according to 
the psychopathological subtypes. Retention rates differed 
statistically between the five subgroups (Wilcoxon sta-
tistics = 17.19; df = 4; p = 0.002). In particular, patients 
with prominent ‘violence-suicide’ symptomatology 
showed a poorer retention rate (52.7% of those entering 
a treatment) than patients with prominent ‘worthless-
ness-being trapped’ (65.4% of entrants; Wilcoxon statis-
tics = 6.02; df = 1; p = 0.014), with prominent ‘somatic 
symptoms’ (57.0% of entrants; Wilcoxon statistics = 4.35; 
df = 1; p = 0.037), with prominent ‘sensitivity psychoti-
cism’ (63.8% censored; Wilcoxon statistics  =  11.60; 
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df  =  1; p  =  0.001) and with prominent ‘panic anxiety’ 
symptomatology (63.3% of entrants; Wilcoxon statis-
tics = 11.60; df = 1; p = 0.000),
Correlation between primary substance of abuse together 
with prominent psychopathology and residential 
treatment outcome
Table 1 shows the correlation between primary substance 
of abuse together with prominent psychopathology and 
residential treatment outcome corrected by demographic 
and clinical characteristics. Only age correlated nega-
tively with dropping out of residential treatment. Oldest 
patients tended to remain in treatment longer than the 
youngest ones. Cocaine use disorder patients remained 
in treatment for a shorter time than heroin use disorder 
ones. Not having been detoxified at residential treatment 
entry and the presence of psychopathological symptoms 
were the two factors that influenced the outcome nega-
tively. The prominent ‘somatic symptoms’ and ‘violence-
suicide’ symptomatology at treatment entry correlated 
positively with dropout from the therapeutic community.
Discussion
The ‘worthlessness-being trapped’ psychopathological 
domain leads to a longer retention in treatment than the 
other four prominent psychopathological groups. On the 
other hand, the ‘somatic symptoms’ and ‘violence-suicide 
symptoms’ groups correlate with dropout from residen-
tial treatment. When considering various different drugs 
of dependence, cocaine use disorder (CUD) patients 
show outcomes worse than HUD individuals. At a mul-
tivariate level, age, detoxified status and total number of 
psychopathological symptoms influence outcomes nega-
tively, especially in the case of CUD.
The severity of psychopathology appears to have a cru-
cial impact on retention rate in treatment progression. In 
line with this, the presence of psychiatric comorbidity has 
been shown to have a general negative prognostic signifi-
cance when opioid maintenance treatment programmes 
were studied [11, 22–24]. Wide discrepancies in results 
have, however, been found [13–16, 18, 25] with several 
studies showing no influence on retention in treatment 
[14–18, 25, 26], whereas other studies reported a sub-
stantial difference in retention, whether based on the 
presence of a mental disorder [27] or in considering spe-
cifically psychopathological traits, such as those located 
on DSM Axis II [13, 28]. In addition, the impact of psy-
chiatric comorbidity has been studied in TCs, whereas 
the highest dropout frequency has been observed in 
patients with the highest severity of psychiatric problems 
[29, 30].
Moreover, the correlation between psychopathology 
severity and retention in treatment increases substan-
tially when looking at specific psychopathological dimen-
sions. While the severity of ‘sensitivity-psychoticism’ 
and ‘panic-anxiety’ symptoms did not turn out to inter-
fere with retention, patients belonging to the ‘somatic 
symptoms’ and ‘violence-suicide’ dimensions showed a 
1.31- and 1.46-fold probability, respectively, of leaving 
their treatment compared with those belonging to the 
‘worthlessness-being trapped’ dimension. Physical com-
plaints may be a part of the psychopathological structure 
of addiction, but may also be consistent with the somatic 
consequences of the use of substances, partly as a direct 
effect of their use on specific organs and functions, other 
than intoxication and withdrawal. Moreover, physical 
complaints must be partly attributed to the risk-taking 
style of lives associated with addiction. Lastly, “somati-
zation” has been viewed as a component of the addictive 
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personality, and has been correlated with probable drop-
out from therapeutic programmes [31]. It is, however, 
easy to understand that these complaints tend to act 
in the same way as a stressful condition that induces 
patients to leave their treatment. On the other hand, the 
high probability of leaving TCs that is found in patients 
with ‘violence-suicide’ symptomatology may be explained 
in the light of the psychological and behavioural features 
of this very psychiatric dimension. If we now go through 
the SCL-90 items, besides suicidal thoughts or longings 
for death, patients belonging to this dimension have diffi-
culty in controlling their impulsiveness and rage. In cases 
with this psychological background, it should be easy to 
understand that these patients are likely to show intol-
erance towards peer-based social interactions, to a clear 
system of rules and regulations, and to the approach of 
ensuring that each patient has a long stay in the commu-
nity, all of which supply basic criteria underlying a ther-
apeutic community [32]. Moreover, it is critical to note 
that TC programmes are often distinguished by their 
tendency to avoid a medical approach or any specifically 
psychiatric treatments. Consistently with this explana-
tion, ‘violence-suicide’ dominant dimensions turned out 
to be associated with a preference for OAT when com-
pared with a TC programme [2], due to the positive 
effects of therapeutic opioids on patients’ psychopathol-
ogy [33].
Being older is associated with longer retention in treat-
ment. Easy dropout from treatments designed to combat 
the substance dependence of young people was a feature 
noted in previous studies carried out with large samples 
of participants, although other studies failed to iden-
tify a correlation between age and length of stay in TCs 
[34]. Data from studies that looked specifically at drop-
out from residential TCs are sparse and controversial: a 
majority of studies fail to show any correlation between 
age and retention [35–37]; there has, however, been at 
least one study that shows such a correlation [38]. The 
higher level of impulsivity and risk-taking behaviour 
shown by adolescents and correlated with the process of 
development of brain structures has been hypothesized 
as the explanation for the high likelihood of leaving treat-
ment [39]. Being compliant with TC treatment is surely 
a sign of awareness of illness, and results from this study 
suggest that older addicts show a better level of insight 
than younger ones, in line with previous observations 
providing evidence that the presence of insight correlates 
with the progression of the toxicomanic process [40].
When different drugs of addiction are compared, CUD 
patients show the highest dropout levels from TC pro-
grammes. This result may depend on the effects exerted 
by cocaine on mood and psychological performance. It 
must be considered that sample size (about 2000 partici-
pants) could partly explain the differences that emerge 
from our findings. In any case, the high frequency of 
such dropouts has even been confirmed by Cox regres-
sion, which documented the confounding effects of psy-
chopathology. Considering the kind of substance abused, 
some studies have shown an association of cocaine use 
with dropout [41–45], but this has not been confirmed 
Table 1 Correlations between residential treatment negative outcomes and associated covariates
a Considering prominent ‘worthlessness-being trapped’ as reference group
b Considering heroin as the reference primary substance of abuse
Variables B Exp(B) 95% CI Sig
Age −0.02 0.98 0.98–0.99 0.001
Gender (female) −0.06 0.94 0.77–1.15 0.566
Civil status (with partner) −0.05 0.96 0.75–1.21 0.707
Education (lasting <8 years) 0.02 1.02 0.85–1.22 0.835
Living with parents −0.05 0.95 0.81–1.12 0.548
Entering therapeutic communities without having been detoxified 0.58 1.79 1.55–2.07 0.000
Total SCL90 at treatment entry 0.002 1.002 1.001–1.004 0.000
SCL90 typologya 0.015
 Prominent somatic symptoms 0.27 1.31 1.03–1.67 0.028
 Prominent sensitivity‑psychoticism symptoms 0.08 1.09 0.84–1.40 0.520
 Prominent panic‑anxiety symptoms 0.16 1.17 0.92–1.49 0.207
 Prominent violence‑suicide symptoms 0.38 1.46 1.14–1.87 0.003
Primary substance of abuseb 0.036
 Alcohol 0.03 1.04 0.84–1.27 0.742
 Cocaine 0.21 1.23 1.05–1.45 0.011
Statistics: Chi square 131.21, df 13, p = 000
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in studies carried out in therapeutic communities [35, 38, 
46].
The strong correlation between intoxication status and 
dropout from TC programmes can hardly be considered 
surprising. The finding that the probability of dropout 
in people who had not been detoxified was almost dou-
ble (exp. 1.79) that of detoxified patients can easily be 
understood considering the extreme susceptibility of 
patients with addiction problems to cues and conditions 
related to drug use, and the primary role played by with-
drawal in craving and relapse. On these bases, it is easy 
to understand how a patient complaining about physical 
and psychological symptoms may choose to dropout of 
residential treatment. This may be observed especially 
in abstinence-oriented TC programmes, which appear 
to lead to undervaluation of the impact of withdrawal on 
willingness to stay in treatment.
Limitations
As to limitations, it must be considered that some of 
the important determinants of retention in treatment, 
including those that may be associated with psycho-
pathological severity, were left out of consideration in 
this study. First, only heroin, cocaine and alcohol were 
considered as the primary substance of abuse, while the 
possible secondary use of these substances or the use of 
other substances (including cannabis, nicotine and hal-
lucinogens) as possible determinants of dropout was 
not discussed. Second, the presence of specific formal 
psychiatric diagnoses was not recorded: the availability 
of formal psychiatric diagnoses, besides giving informa-
tion on the association between specific mental disorders 
and dropout, would also have made it possible to look at 
potential correlations between psychiatric disorders and 
psychopathological dimensions. Third, interventions car-
ried out in TCs in the form of delivering psychological 
and psychiatric care, the availability of pharmacological 
interventions and the presence of psychosocial services 
were not collected; all these are factors that may act as 
confounders of the relationship between psychopathol-
ogy and retention in treatment.
Other limits to the validity of the five SCL-90-based 
psychopathological dimensions solution have been dis-
cussed in previous studies on the SCL-90-defined struc-
ture of the psychopathology of opioid addiction [1] and 
on the same population [2, 8, 9]. In these studies, the 
neglected factor has been the lack of any observer-related 
‘objective’ evaluation, as SCL-90 is a self-administered 
instrument that may be affected by the voluntary or 
involuntary hiding of some symptoms.
Finally, a further limitation is that in this analysis the 
SCL-90 questionnaire was administered at treatment 
entry only, and hence, results can only be considered 
representative of subjects with addiction at that initial 
moment. Some symptoms may vary at different stages of 
the disease so that they may prove to be under- or over-
weighed in our sample.
Conclusions
Length of retention in treatment of patients entering 
TC treatment is significantly lower for those who have 
a more severe psychopathology. Moreover, patients with 
prominent ‘violence-suicide’ and ‘somatic’ symptoms 
may leave the treatment earlier than those allocated to 
the other three psychopathological dimensions resulting 
from the application of PCA to the SCL-90 responses (i.e. 
‘worthlessness-being trapped’, ‘sensitivity-psychoticism’ 
and ‘panic-anxiety’). The SCL-90 five-factorial structure 
of the psychopathology of substance dependence could 
turn out to be a useful tool when applied as a prognostic 
factor, together with age, detoxification status and kind 
of substance of abuse, all of which have been shown to 
influence retention in treatment at multivariate level.
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